Trial Profile

A Randomized Double Blind-placebo Controlled Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 in Participants With Ankylosing Spondylitis (AS)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sarilumab (Primary)
Indications Ankylosing spondylitis
Focus Therapeutic Use
Acronyms ALIGN
Sponsors Sanofi

Most Recent Events

18 Feb 2014 Results published in the Annals of the Rheumatic Diseases.
30 Oct 2013 Tolerability results from a post hoc analysis presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
06 Aug 2012 Actual patient number changed from 300 to 301 as reported by ClinicalTrials.gov (Parent trial: NCT01061723).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com